
In a recent study, Efgartigimod, an engineered human IgG1 antibody Fc fragment, demonstrated promising results in the treatment of Generalized Myasthenia Gravis (gMG). The study, known as the ADAPT study, assessed the safety and efficacy of Efgartigimod, showing significant enhancements in Myasthenia Gravis Activities of Daily Living (MG‐ADL) and Quantitative Myasthenia Gravis (QMG) scores. This post hoc analysis revealed substantial improvements in muscle function and strength across all muscle groups, signifying the potential of Efgartigimod in effectively managing gMG.
Like
Save
Share